“Restoring sight to the blind”: what Neuralink’s Blindsight implant can actually do
“Restoring sight to the blind”: what Neuralink’s Blindsight implant can actually do Elon Musk has announced that Neuralink…

“Restoring sight to the blind”: what Neuralink’s Blindsight implant can actually do Elon Musk has announced that Neuralink…

The European medicines committee issued a positive opinion on Susvimo on 24 July 2026 — a reservoir implanted in the eye that releases ranibizumab continuously and brings injections down to two refills a year. What the comparison with monthly injections really shows about vision, and the price paid in ocular complications.

On 22 July 2026, Science Corporation announced CE marking for PRIMA, a 2-millimetre chip implanted beneath the retina that allows patients with advanced dry AMD to read letters again. The PRIMAvera trial, published in the New England Journal of Medicine, reports a clinically meaningful improvement in 26 of 32 patients at twelve months. The widely quoted figure of 25 letters comes from the manufacturer press release and describes only the patients who responded.

On 23 July 2026, France’s medicines agency listed eleven eye drops under supply pressure, led by fluorescein and Mydriaticum. Dr Tourabaly explains what these drops are used for, why single-dose vials run short first, and what to do as a patient.

An autograft of the macula and anterior segment, from one eye to the other, has restored partial vision to an Italian patient. What was actually transplanted, and why the technique cannot be transposed to AMD.

Solar retinopathy is a photochemical burn of the photoreceptors at the centre of the retina. Nothing is felt at the time; symptoms appear hours later, and modern imaging has changed what we know about the prognosis.
Blue-light glasses: are they really worth it? Blue-light-filtering lenses are marketed as protection against screen-related eye strain, retinal…
End of content
End of content